Aim: To evaluate the efficacy of scopolamine administered transdermally for the treatment of drooling in severely disabled patients.
Methods: A prospective, randomized, double-blind, crossover, placebo-controlled clinical trial was designed. The study group consisted of 30 handicapped patients with persistent drooling.